BUSINESSJul 27 · 13:49 UTCSTAT NEWSAndrew Joseph

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

Sarepta Therapeutics appointed Michael Severino, formerly CEO of Tessera Therapeutics, as its new chief executive. The company, which has three Duchenne muscular dystrophy treatments approved, faces ongoing questions about their effectiveness and regulatory scrutiny over gene therapy safety, contributing to a decline in its share price.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Sarepta TherapeuticsorganizationMichael SeverinopersonTessera TherapeuticsorganizationDoug IngrampersonDuchenne muscular dystrophytopicgene therapytopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 1 · 12:31 UTC
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
BUSINESSMay 29 · 13:14 UTC
STAT+: Allogene CEO David Chang stepping down
HEALTHJun 24 · 11:55 UTC
STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval
HEALTHMay 14 · 11:00 UTC
STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
BUSINESSJun 22 · 06:53 UTC
STAT+: Sanofi names new R&D head as it tries to jumpstart pipeline